Clinical trials: Dasatinib
Pancreatic Cancer Metastatic
Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma
The purpose of this research study is to determine if the study drug, dasatinib, given in combination with 5-Fluorouracil, leucovorin and oxaliplatin (FOLFOX) will work against metastatic pancreatic cancer.
- Trial name
- FOLFOX-D (NCT01652976)
- Testing
- Dasatinib, mFOLFOX6
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Florida
Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia
Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
The purpose of this study is assess the effects of the investigational drug dasatinib on participants who are in chronic phase Philadelphia chromosome chronic myeloid leukemia and who are either resistant to or intolerant of…
- Trial name
- NCT00101660
- Testing
- Dasatinib
- Where
- 85 sites in United States, Australia and 20 more
- Volunteers
- 387 people
- Sponsor
- Bristol-Myers Squibb
Prostatic Neoplasms
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
The purpose of this study is to determine whether survival can be prolonged in patients with castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.
- Trial name
- READY (NCT00744497)
- Testing
- Dasatinib, Docetaxel, Prednisone
- Where
- 186 sites in United States, Argentina and 23 more
- Volunteers
- 1,930 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloid Leukemia, Ph+ Acute Lymphoblastic Leukemia
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with philadelphia chromosome-positive (Ph+)…
- Trial name
- PACE (NCT01207440)
- Testing
- Ponatinib
- Where
- 42 sites in Australia, Belgium and 9 more
- Volunteers
- 449 people
- Sponsor
- Ariad Pharmaceuticals
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
The goal of this clinical research study is to learn if dasatinib can help to control myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis
- Trial name
- NCT00255346
- Testing
- Dasatinib (BMS-354825)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- M.D. Anderson Cancer Center
Hormone Refractory Prostate Cancer, Recurrent Prostate Cancer
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
This randomized phase II trial is studying the side effects and how well giving cediranib maleate together with or without dasatinib works in treating patients with hormone-resistant prostate cancer resistant to treatment with…
- Trial name
- NCT01260688
- Testing
- cediranib maleate, dasatinib
- Where
- 8 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Kidney Disease
Senescence in Chronic Kidney Disease
The study goal is to assess the effect of senescent cell clearance on senescence burden, physical ability or frailty, and adipose tissue-derived mesenchymal stem cell (MSC) functionality in patients with chronic kidney disease…
- Trial name
- NCT02848131
- Testing
- Group 2: Dasatinib, Group 2: Quercetin
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Diffuse Intrinsic Pontine Glioma, High-grade Glioma
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
This is a phase I study to find the highest tolerable dose of crizotinib and dasatinib given in combination to patients with diffuse intrinsic pontine glioma (DIPG) and other types of high grade gliomas (HGG).
- Trial name
- NCT01644773
- Testing
- Crizotinib, Dasatinib
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- St. Jude Children's Research Hospital
Aging
Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging
Assessing the effects of Quercitin and Dasatinib over a 16 week period on participatns' epigenetic biological aging. The patients are being tested at baseline, halfway point, and after the trial period.
- Trial name
- NCT04946383
- Testing
- Dasatinib plus Quercetin
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- TruDiagnostic
Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
This phase II trial is studying how well dasatinib works in treating patients with relapse small cell lung cancer. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Trial name
- NCT00470054
- Testing
- dasatinib
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
The design of a phase I, open label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent ABL001 in Chronic myeloid leukemia (CML) and Philadelphia chromosome positive Acute lymphoblastic…
- Trial name
- NCT02081378
- Testing
- Asciminib (ABL001), Nilotinib, Imatinib
- Where
- 18 sites in United States, Australia and 8 more
- Volunteers
- 326 people
- Sponsor
- Novartis Pharmaceuticals
Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer
The purpose of this research study is to find out if a new anti-cancer drug, dasatinib (Sprycel®), previously approved for treatment of some forms of leukemia, will be safe and helpful in treating patients with hormone-refractory…
- Conditions
- Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Prostate Cancer
- Trial name
- NCT00570700
- Testing
- Dasatinib
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of California, Irvine
Recurrent Childhood Brain Tumor
Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
This research study is a Feasibility clinical trial. In this trial, researchers are trying to figure out whether a medication can be chosen based on rapid testing done on tumor tissue.
- Trial name
- SEED (NCT02015728)
- Testing
- Tumor biology testing, Temozolomide, Etoposide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Seattle Children's Hospital
Acute Myeloid Leukemia
The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia
The purpose of this study is to evaluate that whether the AML (acute myeloid leukemia)-CAMS (Chinese Academy of Medical Sciences)-2016 regimen, includes risk-stratified therapy and the use of Dasatinib in CBF (Core binding…
- Trial name
- NCT03173612
- Testing
- Dasatinib
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Inflammatory Carcinoma
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
This phase Ib/II tests the safety, side effects, and best dose of icosapent ethyl in combination with dasatinib and whether they work to shrink tumors in patients with triple-negative inflammatory breast cancer that has spread to…
- Trial name
- NCT05198843
- Testing
- Dasatinib, Icosapent Ethyl
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Myeloid Leukemia, Chronic, Chronic-Phase
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
This is a phase III study of BMS-354825 in subjects with chronic phase Philadelphia chromosome or BCR-ABL positive chronic myelogenous leukemia, who are resistant or intolerant to imatinib mesylate (Gleevec).
- Trial name
- NCT00123474
- Testing
- dasatinib
- Where
- 137 sites in United States, Argentina and 29 more
- Volunteers
- 724 people
- Sponsor
- Bristol-Myers Squibb
Leukemia
Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study
This is a retrospective, multicenter, descriptive analysis of patients with a diagnosis of chronic myeloid leukemia, treated with dasatinib for at least 45 days.
- Trial name
- PASS (NCT02546791)
- Testing
- Dasatinib
- Volunteers
- 101 people
- Sponsor
- Bristol-Myers Squibb
Peripheral T Cell Lymphoma
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
This is a multicenter, prospective, open-label, interventional umbrella study to evaluate the efficacy and safety of targeted therapies guided by molecular subtypes in patients with relasped or refractory peripheral T-cell…
- Trial name
- NCT05559008
- Testing
- Azacitidine Injection, Dasatinib, Linperlisib
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Ruijin Hospital
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
This phase II trial studies how well etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (DA-EPOCH) works in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma.
- Trial name
- NCT03023046
- Testing
- Cyclophosphamide, Dasatinib, Doxorubicin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Washington
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
This phase Ib trial studies the effects of venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) that is…
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia
- Trial name
- NCT04872790
- Testing
- Dasatinib, Methotrexate, Prednisone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- OHSU Knight Cancer Institute